WADA prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-07. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
== Contraindications == Levothyroxine is contraindicated in people with hypersensitivity to levothyroxine sodium or any component of the formulation, people with acute myocardial infarction, and people with thyrotoxicosis of any etiology. Levothyroxine is also contraindicated for people with uncorrected adrenal insufficiency, as thyroid hormones may cause an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids. For oral tablets, the inability to swallow capsules is an additional contraindication.
=== Inquiries into the paranormal === Jung had an apparent interest in the paranormal and occult. For decades, he attended seances and claimed to have witnessed "parapsychic phenomena". Initially, he attributed these to psychological causes, even delivering a 1919 lecture in England for the Society for Psychical Research on "The Psychological Foundations for the belief in spirits". However, he began to "doubt whether an exclusively psychological approach can do justice to the phenomena in question" and stated that "the spirit hypothesis yields better results". Still, he retained some skepticism toward his own postulation, as he could not find material evidence of the existence of spirits. Jung's ideas about the paranormal culminated in "synchronicity". This is the idea that certain coincidences manifest in the world, have exceptionally intense meaning to observers. Such coincidences have a great effect on the observer from multiple cumulative aspects: from the immediate personal relevance of the coincidence to the observer, from the peculiarities of (the nature of, the character, novelty, curiosity of) any such coincidence; from the sheer improbability of the coincidence, having no apparent causal link (hence Jung's essay subtitle "An Acausal Connecting Principle"). Despite his own experiments failing to confirm the phenomenon he held on to the idea as an explanation for apparent ESP. In addition, he proposed it as a functional explanation for how the I-Ching worked. However, he was never clear about how synchronicity worked.
== Publications == Derivatives of Columbium and Tantalum, J. Am. Chem. Soc. 1896, 18, 1, 38–67, January 1, 1896 Studies of Poultry from the Farm to the Consumer, Washington, D.C.: U.S. Department of Agriculture, 1910 The Refrigeration of Dressed Poultry in Transit, U.S. Department of Agriculture, 1913 How to Kill and Bleed Market Poultry, Washington D.C.: U.S. Government Printing Office, 1915 A Study of the Preparation of Frozen and Dried Eggs in the Producing Section, Washington, D.C.: U.S. Department of Agriculture, 1916 How to Candle Eggs, Washington D.C.: U.S. Department of Agriculture, 1918 The Prevention of Breakage of Eggs in Transit When Shipped in Carlots, Washington, D.C.: U.S. Department of Agriculture, 1918
MK-2870 or SKB264 is an experimental antibody–drug conjugate. The antibody component is directed against "the trophoblast cell-surface antigen 2 (TROP2), which is overexpressed in many types of solid tumors, coupled to moderate cytotoxic belotecan-derivative through a novel linker which was designed to balance the extracellular stability and intracellular rupture". The drug is developed as a partnership between Merck and the Chinese company Kelun-Biotech.
==== De Novo synthesis ==== The de novo biosynthesis of arginine in humans begins with glutamine. This compound is deaminated to glutamic acid and subsequently converted to glutamate-5-semialdehyde. Transamination of a second glutamic acid molecule produces ornithine, which enters the urea cycle.
Sources: en.wikipedia.org
== Commercialization == 1-MNA has been approved for use in food products in the form of 1-MNA chloride. The approval process in the European Union was successfully completed by PHARMENA SA. In 2017, the European Food Safety Authority (EFSA) confirmed the safety of 1-MNA chloride in food supplements, leading to its authorization in 2018 under EU Regulation 2018/1123. 1-MNA chloride is currently used in dietary supplements. Other chemical forms of 1-MNA are not currently allowed on the market as food.
A period of rule under the Swedish House of Vasa began in the Commonwealth in the year 1587. The first two kings from this dynasty, Sigismund III (r. 1587–1632) and Władysław IV (r. 1632–1648), repeatedly attempted to intrigue for accession to the throne of Sweden, which was a constant source of distraction for the affairs of the Commonwealth. At that time, the Catholic Church embarked on an ideological counter-offensive and the Counter-Reformation claimed many converts from Polish and Lithuanian Protestant circles. In 1596, the Union of Brest split the Eastern Christians of the Commonwealth to create the Uniate Church of the Eastern Rite, but subject to the authority of the pope. The Zebrzydowski rebellion against Sigismund III unfolded in 1606–1608. Seeking supremacy in Eastern Europe, the Commonwealth fought wars with Russia between 1605 and 1618 in the wake of Russia's Time of Troubles; the series of conflicts is referred to as the Polish–Russian War or the Dymitriads. The efforts resulted in expansion of the eastern territories of the Polish–Lithuanian Commonwealth, but the goal of taking over the Russian throne for the Polish ruling dynasty was not achieved. Sweden sought supremacy in the Baltic during the Polish–Swedish wars of 1617–1629, and the Ottoman Empire pressed from the south in the Battles at Cecora in 1620 and Khotyn in 1621. The agricultural expansion and serfdom policies in Polish Ukraine resulted in a series of Cossack uprisings.
== Realism and balancing == The balance of power theory is a core tenet of both classical and neorealist theory and seeks to explain alliance formation. Due to the neorealist idea of anarchism as a result of the international system, states must ensure their survival through maintaining or increasing their power in a self-help world. With no authority above the state to come to its rescue in the event of an attack by a hegemon, states attempt to prevent a potential hegemon from arising by balancing against it. According to Kenneth Waltz, founder of neorealism, "balance-of-power politics prevail wherever two, and only two requirements are met: that the order be anarchic and that it be populated by units wishing to survive". They can do this either through "internal balancing", where a state uses internal efforts such as moving to increase economic capability, developing clever strategies and increasing military strength, or through "external balancing", which occurs when states take external measures to increase their security by forming allies. As states are assumed to be skeptical of the intentions of other states, neorealists primarily hold that states balance through "self-help", as they expand their military capabilities and copy military innovations of competitors. States happy with their place in the system are known as "status quo" states, while those seeking to alter the balance of power in their favor are generally referred to as "revisionist states" and aspire for hegemony, thus repairing the balance.
Self-amplifying mRNA (saRNA) vaccines replicate their mRNA after transfection. Self-amplifying mRNA has two open reading frames. The first frame, like conventional mRNA, codes for the antigen of interest. The second frame codes for an RNA-dependent RNA polymerase (and its helper proteins) which replicates the mRNA construct in the cell. This allows smaller vaccine doses. The mechanisms and consequently the evaluation of self-amplifying mRNA may be different, as self-amplifying mRNA is a much bigger molecule. SaRNA vaccines being researched include a malaria vaccine. The first saRNA Covid vaccine authorised was Gemcovac, in India in June 2022. The second was ARCT-154, developed by Arcturus Therapeutics. A version manufactured by Meiji Seika Pharma was authorised in Japan in November 2023. GSK began a phase 1 trial of an saRNA COVID-19 vaccine in 2021. Gritstone bio started also started a phase 1 trial of an saRNA COVID-19 vaccine in 2021, used as a booster vaccine, with interim results published in 2023. The vaccine is designed to target both the spike protein of the SARS‑CoV‑2 virus, and viral proteins that may be less prone to genetic variation, to provide greater protection against SARS‑CoV‑2 variants. saRNA vaccines must use uridine, which is required for reproduction to occur.
Sources: en.wikipedia.org
Taisei Hokan Imperial Rescript on Education Imperial Rescript to Soldiers and Sailors Japanese Taiwan Japanese Korea Japanese nationalism List of political figures of Meiji Japan Meiji Memorial Picture Gallery Rising Sun Flag High Treason Incident Battle of Pyongyang (1894) Battle of Yalu River (1894) Battle of Jiuliancheng 1874 Japanese expedition to Taiwan Japanese invasion of Taiwan (1895) Ryukyu Disposition Shrine Consolidation Policy
== Publications == Maroon has published over 340 peer-reviewed scientific articles, some of which may be found in the United States National Library of Medicine's publication database; his H-index, a measure of scientific research impact, is 74 (as of June 2025). As of early 2026, his work has garnered more than 27,300 total citations. Currently, Maroon is working with Dr. Pravat K. Mandal and has proposed oxidative stress as the underlying pathogenesis of Alzheimer's disease and Parkinson's disease.
The ribosome has three binding sites for tRNA molecules that span the space between the two ribosomal subunits: the A (aminoacyl), P (peptidyl), and E (exit) sites. In addition, the ribosome has two other sites for tRNA binding that are used during mRNA decoding or during the initiation of protein synthesis. These are the T site (named elongation factor Tu) and I site (initiation). By convention, the tRNA binding sites are denoted with the site on the small ribosomal subunit listed first and the site on the large ribosomal subunit listed second. For example, the A site is often written A/A, the P site, P/P, and the E site, E/E. The binding proteins like L27, L2, L14, L15, L16 at the A- and P- sites have been determined by affinity labeling by A. P. Czernilofsky et al. (Proc. Natl. Acad. Sci, USA, pp. 230–234, 1974). Once translation initiation is complete, the first aminoacyl tRNA is located in the P/P site, ready for the elongation cycle described below. During translation elongation, tRNA first binds to the ribosome as part of a complex with elongation factor Tu (EF-Tu) or its eukaryotic (eEF-1) or archaeal counterpart. This initial tRNA binding site is called the A/T site. In the A/T site, the A-site half resides in the small ribosomal subunit where the mRNA decoding site is located. The mRNA decoding site is where the mRNA codon is read out during translation. The T-site half resides mainly on the large ribosomal subunit where EF-Tu or eEF-1 interacts with the ribosome.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.